Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Basilea Launches Complementary Phase III Trial For Anti-infective Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

New trial adds to data on isavuconazole for invasive yeast and mold infections.

You may also be interested in...



FDA Wants More Ceftobiprole Data From J&J/Basilea

Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.

CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients

After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.

Novartis Looks To Take Its Diversity Show On The Road

Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.

Topics

UsernamePublicRestriction

Register

PS067573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel